1686.1 – 177 Lutetium PSMA i&t for metastatic castrate resistant prostate cancer

New MBS item.

177 Lutetium PSMA i&t is a targeted radionuclide radiotherapy that enters the cancer cell via the PSMA receptor, which is overexpressed in prostate cancer, with expression increasing in metastatic and castrate resistant disease. Therapy is intended for patients with progressive metastatic castrate resistant prostate cancer after the disease has progressed despite chemotherapy. Screening with PSMA Positron Emission Tomography (PET) and FDG PET determines if the patient has an adequate level of PSMA ‘target’ at all sites of measurable disease such that they will be expected to derive significant benefit from the treatment.

Type: Therapeutic technology

Prostate cancer is one of the commonest cancers in Australia. Castrate-resistant prostate cancer is defined by disease progression despite androgen depletion therapy (reducing the amount of testosterone in the body) and may present as either a continuous rise in serum prostate-specific antigen levels (usually elevated in men with prostate cancer), the progression of pre-existing disease, and/or the appearance of new metastases.

• PASC consultation: Not applicable
• MSAC consultation: Closed Friday 16 February 2024

• PASC meeting: Bypassed PASC
• ESC meeting: 
  • 8–9 June 2023 
  • 15–16 February 2024
• MSAC meeting: 
  • 27–28 July 2023 
  • 4–5 April 2024